Skip to main content
. Author manuscript; available in PMC: 2023 Apr 7.
Published in final edited form as: J Pain. 2022 Nov 20;24(4):605–616. doi: 10.1016/j.jpain.2022.11.006

Figure 5.

Figure 5.

C781 attenuates the pronociceptive effects of the mast cell degranulator, compound 48/80. Baseline (BL) paw withdrawal thresholds and grimace scores for male and female ICR mice were obtained before hind paw injection with compound 48/80 and C781 intraperitoneal injection. C781 (10 and 30 mg/kg i.p.) was injected 30 minutes before compound 48/80 (0.2 ug i.pl.) paw injection, and (A) von Frey withdrawal threshold and (B) grimace scores were assessed after compound 48/80 injection. For the C781 (10 mg/kg) group, n = 4 females, and n = 3 males. For the C781 (30 mg/kg) group, n = 4 females and n = 4 males. For the Vehicle group, n = 6 females and n = 8 males. *P < .05, **P < .01, ***P < .001. For paw withdrawal threshold and grimace scores, repeated measures 2-way ANOVA with Dunnett post-test was used. All group mean comparisons were made to the mean of the Vehicle group.